9380 related articles for article (PubMed ID: 19445369)
1. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
2. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
3. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Obeid M; Ortiz C; Criollo A; Mignot G; Maiuri MC; Ullrich E; Saulnier P; Yang H; Amigorena S; Ryffel B; Barrat FJ; Saftig P; Levi F; Lidereau R; Nogues C; Mira JP; Chompret A; Joulin V; Clavel-Chapelon F; Bourhis J; André F; Delaloge S; Tursz T; Kroemer G; Zitvogel L
Nat Med; 2007 Sep; 13(9):1050-9. PubMed ID: 17704786
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
6. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic anti-cancer chemotherapy as an emerging concept.
Haynes NM; van der Most RG; Lake RA; Smyth MJ
Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
9. The immune system--is it relevant to cancer development, progression and treatment?
Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic cell death modalities and their impact on cancer treatment.
Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
[TBL] [Abstract][Full Text] [Related]
11. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
13. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
[TBL] [Abstract][Full Text] [Related]
14. [Antitumoral immunization during cancer chemotherapy].
Zitvogel L; Hannani D; Aymeric L; Kepp O; Martins I; Kroemer G
Bull Acad Natl Med; 2012 Jun; 196(6):1075-86. PubMed ID: 23596856
[TBL] [Abstract][Full Text] [Related]
15. Desirable cell death during anticancer chemotherapy.
Locher C; Conforti R; Aymeric L; Ma Y; Yamazaki T; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Morel Y; Girard JP; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2010 Oct; 1209():99-108. PubMed ID: 20958322
[TBL] [Abstract][Full Text] [Related]
16. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
Radfar S; Wang Y; Khong HT
J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
[TBL] [Abstract][Full Text] [Related]
17. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
18. Immunological aspects of cancer chemotherapy.
Zitvogel L; Apetoh L; Ghiringhelli F; Kroemer G
Nat Rev Immunol; 2008 Jan; 8(1):59-73. PubMed ID: 18097448
[TBL] [Abstract][Full Text] [Related]
19. A novel vicious cycle cascade in tumor chemotherapy.
Zhou H; Zou P; Chen ZC; You Y
Med Hypotheses; 2007; 69(6):1230-3. PubMed ID: 17555885
[TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant chemo- and radiotherapy on the cellular immune system of breast cancer patients.
Mellios T; Ko HL; Beuth J
In Vivo; 2010; 24(2):227-30. PubMed ID: 20364000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]